GlassScriptPhysician profile
Alberto Sirven
NPI 1639107212
$16,584.73
in general payments reported to CMS, 2019-2025
38 companies · $3,876 in 2025
The $3,876 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $133 · 2021: $598 · 2022: $735 · 2023: $7,547 · 2024: $2,500 · 2025: $3,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,587.50 |
| Food and Beverage | $2,335.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $11,920.22 | 2023-2025 | Veozah |
| Abbvie INC. | $751.44 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Coloplast Corp | $686.11 | 2019-2025 | |
| Coopersurgical, INC. | $584.46 | 2019-2025 | Ally II Ups, Paragard T 380a, Advincula Delineator Uterine Manipulator |
| Hologic Sales and Service, LLC | $425.82 | 2020-2025 | Acessa Provu System |
| Caldera Medical, INC | $331.69 | 2022-2023 | Desara |
| Daiichi Sankyo INC. | $272.22 | 2019-2024 | Injectafer |
| Laborie Medical Technologies Corp. | $219.59 | 2019 | |
| Csl Behring | $169.24 | 2022-2025 | Andembry, Haegarda |
| Femselect INC. | $158.60 | 2025 | Enplace |
| Organogenesis INC. | $140.41 | 2024 | Nushield |
| Pfizer INC. | $110.67 | 2019-2025 | |
| Vertical Pharmaceuticals, LLC | $89.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $81.98 | 2023-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $68.69 | 2022-2024 | Takhzyro |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Channel Medsystems, INC. | $56.09 | 2023 | |
| Organon LLC | $54.54 | 2022-2025 | Nexplanon |
| Medicem INC. | $42.04 | 2022-2023 | |
| Optinose US, INC. | $37.72 | 2022-2023 | |
| Biocryst US Sales Co., LLC | $32.50 | 2025 | Orladeyo |
| Mission Pharmacal Company | $28.93 | 2019 | |
| Hologic INC | $25.56 | 2021 | |
| Boston Scientific Corporation | $25.51 | 2023 | |
| Allergan, INC. | $24.89 | 2019-2020 | |
| Covidien LP | $24.64 | 2019 | |
| Blueprint Medicines Corporation | $24.60 | 2025 | Ayvakit |
| Optumhealth Care Solutions, LLC | $22.54 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Myovant Sciences INC. | $21.09 | 2022 | |
| Ethicon US, LLC | $20.83 | 2021 | |
| Therapeuticsmd, INC. | $19.78 | 2021 | |
| Pharming Healthcare, INC. | $18.25 | 2023 | Ruconest |
| Sanara Medtech INC. | $18.24 | 2024 | Celleraterx |
| Mayne Pharma Commercial LLC | $18.13 | 2021 | |
| Urovant Sciences INC | $17.99 | 2022 | |
| Kci USA, INC. | $14.38 | 2019 | |
| Millicent US INC | $13.66 | 2020 | |
| Duchesnay USA Incorporated | $11.76 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Sirven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.